Strategy
MSTR
Meta Platforms
META
Oracle
ORCL
Amazon
AMZN
Salesforce
CRM
US Stock MarketDetailed Quotes
PPBT Purple Biotech
- 3.050
- +0.110+3.74%
Close Feb 26 16:00 ET
7.88MMarket Cap-0.41P/E (TTM)
3.070High2.840Low21.54KVolume2.880Open2.940Pre Close63.17KTurnover0.86%Turnover RatioLossP/E (Static)2.58MShares20.60052wk High0.27P/B7.66MFloat Cap2.00052wk Low--Dividend TTM2.51MShs Float1390.000Historical High--Div YieldTTM7.82%Amplitude2.000Historical Low2.932Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Purple Biotech Stock Forum
Revolutionary Cancer Drug NT219 Enters Phase 2 Trial Targeting $5B Market Opportunity
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Tuesday, 18th February at 7:00 am
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)
The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led by Dr. Antonio Jimeno, Professor and Director of ...
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
Thursday, 5th December at 7:13 am
REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced registered direct offering o...
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
Tuesday, 3rd December at 8:23 am
REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a definitive agreement for the purchase and sale of 472,...
📊⚡️📊
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
No comment yet